Business Context and Reporting Period
This Form 8-K is filed by PowerUp Acquisition Corp. (not Aspire Biopharma Holdings, Inc.) on June 6, 2024. The filing reports the entry into Amendment No. 1 to the Agreement and Plan of Merger with Visiox Pharmaceuticals, Inc. The transaction involves a merger where Visiox will become a wholly-owned subsidiary of PowerUp.
Key Financial Metrics and Terms
The filing details specific financial conditions and thresholds modified by the amendment rather than reporting historical operating results:
- Indebtedness Cap: Increased from $1 million to $2 million.
- Minimum Cash Condition: Reduced from $5 million to $1.00.
- Net Tangible Assets: The requirement for PowerUp to have net tangible assets of at least $5,000,001 at closing has been eliminated.
- Capital Raise Requirement: Visiox is required to raise at least $500,000 on or before June 30, 2024.
- Expenditure Limit: Visiox is restricted from making expenditures exceeding $1,000 without PowerUp's approval (excluding ordinary payroll) from May 30, 2024, until closing.
Note: The filing does not provide revenue, profit, cash flow, or margin data for either entity.
Material Changes Versus Prior Period
The primary material change is the extension of the transaction timeline and the relaxation of financial closing conditions:
- Outside Date Extension: The deadline to complete the transaction was extended from May 31, 2024, to June 30, 2024.
- Condition Relaxation: Significant reductions in the cash and asset requirements previously mandated for closing.
- New Covenants: Addition of specific obligations for Visiox regarding product inventory distribution and capital raising.
Guidance, Outlook, and Risks
The filing contains forward-looking statements regarding the anticipated benefits, timing, and financial performance of the combined company. Management cautions that these statements are subject to risks and uncertainties, including:
- Satisfaction of closing conditions.
- Level of redemptions by PowerUp's public shareholders.
- Future performance and market opportunities of Visiox.
- Regulatory and compliance risks associated with Visiox's product inventory.
Investors are directed to the Registration Statement on Form S-4 (File No. 333-276727) for detailed risk factors.
Investor Verification Checklist
- Verify the status of Visiox's $500,000 capital raise requirement by June 30, 2024.
- Confirm the completion of labeling and compliance requirements for Visiox's current product inventory.
- Review the definitive proxy statement/prospectus (Form S-4) for updated redemption levels and shareholder voting details.
- Monitor the June 30, 2024, Outside Date to determine if the transaction will close or terminate.
- Clarify the discrepancy between the requested company name (Aspire Biopharma) and the filing registrant (PowerUp Acquisition Corp.).